Compounds > troglitazone
Page last updated: 2024-11-05

troglitazone and Leiomyomatosis

troglitazone has been researched along with Leiomyomatosis in 1 studies

Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.

Leiomyomatosis: The state of having multiple leiomyomas throughout the body. (Stedman, 25th ed)

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Tsibris, JC1
Porter, KB1
Jazayeri, A1
Tzimas, G1
Nau, H1
Huang, H1
Kuparadze, K1
Porter, GW1
O'Brien, WF1
Spellacy, WN1

Other Studies

1 other study available for troglitazone and Leiomyomatosis

ArticleYear
Human uterine leiomyomata express higher levels of peroxisome proliferator-activated receptor gamma, retinoid X receptor alpha, and all-trans retinoic acid than myometrium.
    Cancer research, 1999, Nov-15, Volume: 59, Issue:22

    Topics: Alitretinoin; Animals; Carcinogens; Chromans; Drug Implants; Estradiol; Female; Guinea Pigs; Humans;

1999